Drugs / Sonefpeglutide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04775706 | Mar 2022 → Dec 2027 expected | short bowel syndrome | Hanmi Pharmaceutical Company Limited | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Hanmi Pharmaceutical Company Limited | Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) hanmipharm.com ↗ |
| 2024-12-23 | Hanmi Pharmaceutical Company Limited | Hanmi Pharmaceutical's New SBS Drug Secures INN Listing as 'Sonefpeglutide' hanmipharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sonefpeglutide | “Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects” NCT04775706 ↗ |
| Known as | HM15912 | “Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects” NCT04775706 ↗ |
| Route | Subcutaneous | “SC administration” NCT04775706 ↗ |